Transition of Blood Biomarkers During 24-Week Treatment With Lebrikizumab or Tralokinumab in Atopic Dermatitis: A Real-World Analysis Stratified by Prior Systemic Therapy

Background: The transition of blood biomarkers has not been precisely examined in real-world treatments with anti-interleukin (IL)-13 antibodies for atopic dermatitis (AD).Objective: To evaluate the transition of blood biomarkers during 24-week treatment with lebrikizumab or tralokinumab for patients with AD in real-world settings, stratified by the presence or absence of prior systemic therapy.Methods: We conducted a retrospective study of Japanese patients with AD who received lebrikizumab (n = 148) or tralokinumab (n = 173). We measured serum immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), and total eosinophil count (TEC) at weeks 0, 4, 12, and 24 in systemic therapy-naïve or -experienced patients.Results: IgE, TARC, and LDH decreased throughout the 24-week treatment with lebrikizumab or tralokinumab, while TEC transiently increased at week 4 or 12 in both systemic therapy-naïve and -experienced patients, and the magnitudes of decreasing IgE and TARC or increasing TEC were higher in the latter.Conclusion: IgE, TARC, and LDH decreased during 24-week treatment with lebrikizumab or tralokinumab, while TEC transiently increased at week 4 or 12 in both systemic therapy- naïve and -experienced patients.